Shirin Abbasinejad Enger

Dr. Shirin Abbasinejad Enger is an Associate Professor at the Gerald Bronfman Department of Oncology, McGill University, and Director of the Medical Physics Unit. She holds a Tier 2 Canada Research Chair in Medical Physics and serves as research director at the Lady Davis Institute and Segal Cancer Centre (Jewish General Hospital). Her leadership roles include chairing the AAPM's TG-337 (Intensity Modulated Brachytherapy) and contributing to national/international committees on equity and radiation oncology standards.

Education: PhD from Uppsala University (2009), postdoctoral research at Université Laval (2009–2011).

Research focuses on advancing medical physics technologies, with four key axes:

• Novel brachytherapy techniques (e.g., Yb-169 for prostate cancer)
• Radiobiology/microdosimetry (e.g., alpha particle dosimetry)
• Detector development (e.g., scintillating fiber detectors, hydrated electron dosimeters)
• Artificial intelligence integration (e.g., deep learning for dose prediction)

Publications emphasize precision dosimetry, brachytherapy optimization, and medical imaging innovations. Awards include multiple medical innovation prizes and the Young Investigator award at Curietherapies 2022.

Grants and collaborations: Competitive funding for technology translation from concept to clinical trials, with patents on brachytherapy delivery systems and radiation dosimeters. Leads the EngerLab, fostering interdisciplinary research in radiation oncology.